Letter From The Editor

We have had a long relationship with Steven V. Edelman, MD and TCOYD, Our publisher Steve Freed has collaborated with Dr. Edelman to help diabetes patients learn more about diabetes. Dr. Edelman is Editor of the journal Insulin, and we are going to kick off his arrival by having him …

A couple of weeks ago we had a new product blurb about Cycloset™, an old drug with a new indication for diabetes. Many of you wrote to ask me for information on how the medication works and where the idea came from. I had our current PharmD candidate, Robert Fredenrich, …

Last year at the ADA 68th ADA Scientific Sessions, results from the ACCORD and VADT studies indicated that tight glucose control increased the risk of cardiovascular death. This year they reviewed the results again and found that the headlines were unfounded. Now they have reversed their opinions and are saying …

We are back from the 69th ADA Scientific Sessions and there were a lot of new studies, practice pearls and products in development. We have stocked this weeks issue with some of the early highlights and will have more over the next few weeks as our editorial staff has time …

Over the past few weeks, Sheri Colberg, Ph.D., FACSM, has focused on insulin and oral medications and their relationship to exercise and many of you asked about Byetta and Symlin. This week she covers them in Diabetic Medications and Exercise, Part 2: Use of Byetta and Symlin. A TZD without …

A TZD without the side-effects of increased fluid retention and edema, and changes in the vascular and circulating lipids; is that possible? Our current intern Amy Talmage, from the University of Florida College of Pharmacy has found some research that might separate out the players in this class.